PTO/SB/21 (04-07)

Under the Bo			Patent and Tr	Approved for use through 09/30/2007. OMB 0651-0031 ademark Office; U.S. DEPARTMENT OF COMMERCE ormation unless it displays a valid OMB control number.	
Under the Pa	Derwork Reduction Act of 1995, no.	Application Number	10/071,978		
TRANSMITTAL		Filing Date	02/06/2002	02/06/2002	
FORM		First Named Inventor	Eric E. Swa	ayze	
		Art Unit			
(to be used for all correspondence after initial filing)		Examiner Name			
Total Number of Pages in This Submission 12		Attorney Docket Number	IBIS-0028L	us ,	
ENCLOSURES (Check all that apply)					
Amendm A A Extension Express a Informatic		Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocatio Change of Correspondence / Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on Ct Remarks	Address	After Allowance Communication to TC Appeal Communication to Board of Appeals and Interferences Appeals Communication to TC (Appeal Notice, Brief, Repty Brief) Proprietary Information Status Letter United Communication to TC (Please Notice, Brief, Repty Brief) Proprietary Information Status Letter Control Communication Control Communication Control Communication to TC Control Control Communication to TC Control Control Communication to TC Control Cont	
"	nder 37 CFR 1.52 or 1.53				
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm Name Isis Pharmaceuticals, Inc.					
Signature Robert S. amburs					
Printed name	Robert S. Andrews				
7-26-07 R		Reg. No.	44,508		
CERTIFICATE OF TRANSMISSION/MAILING					
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:  Signature					

This collection of information is reguled by 70 CFR 15. The information is required to detain or retain a benefit by the public which is to fits (and by the USPTO to process) an application Confederable by a powered by 30 USB. CTS and 57 CFR 170. The and 14. This collection is estimated to 2 lours to complete, including contenting, preparing, and ulberling the completed application form as to USPTO. It and 14. This collection is estimated to 2 lours to complete in content and annual of the sequence of the content of the conte

Typed or printed name

Date

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OME control number.

(Also Form TPC-1050)

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 11

PATENT NO. : 7,244,847

APPLICATION NO.: 10/071,978 ISSUE DATE : 07/17/2007

INVENTOR(S) : Eric E. Swayze et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

1) Title Page:

Item [54], Title, please insert --Novel-- before "Benzimidazole";

- 2) Item [56], References Cited, OTHER PUBLICATIONS, "Freter" reference, please delete "n-(4-idolylpiperidinoalkyl)" and insert therefor —n-(4-indolylpiperidinoalkyl)—;
- 3) "Fonguerna" reference, please delete "Capluse" and insert therefor -- Caplus--;
- 4) "Agai" reference, please delete "1,3,5,-triazepines, III" and insert therefor --1,3,5,-triazepines. III.--;
- 5) Column 61, Claim 1, lines 14-18, please delete \*

- 6) Column 61, Claim 1, line 22, please insert -- alkyl, -- between "is" and "aryl,";
- 7) Column 61, Claim 1, line 25, please delete "-R<sub>9</sub>-X-R<sub>10</sub>-R<sub>11</sub>)H;" and insert therefor ---R<sub>9</sub>-X-R<sub>10</sub>-(R<sub>11</sub>)H;--;
- 8) Column 61, Claim 1, line 32, please delete ";" and insert therefor --,--;
- 9) Column 61, Claim 1, line 49, please delete "heteroaryl," and insert therefor --heteroaryl or --;

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Isis Pharmaceuticals, Inc.

1896 Rutherford Rd.

Carlsbad, CA 92008

This collection of information is required by 37 CFR 1322, 1323, and 1324. The information is required to obtain or retain a benefit by the public which is to file and by the USPTO to process in a paliciation. Confidentially is governed by \$5 U.S. C.12 and \$7 CFR 1.1.1 This collection is estimated be 1 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. It may very depending upon the individual case. Any comments on the amount of time you require to complete in form and/or supplections for reducing this burden, should be sent to the CERT similar (CERT of the CERT of Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTC-1650)

# UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 2 of 11

PATENT NO. : 7,244,847

APPLICATION NO.: 10/071,978

ISSUE DATE : 07/17/2007

INVENTOR(S) : Eric E. Swayze et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

10) Column 61, Claim 1, line 50, please delete "hereteroaryl" and insert therefor --heteroaryl--;

11) Column 61, Claim 1, line 52, please delete "," and insert therefor --;--;

12) Column 61, Claim 1, line 54, please delete ";" and insert therefor --,--;

Column 61, Claim 1, line 58, please delete "," after "-C(=O)-NH-heteroarylcarbonyl";

14) Column 61, Claim 1, line 61, please delete "," after "cycloalkylaminocarbonyl";

15) Column 62, Claim 1, line 3, please delete "," after "alkylheteroaryl";

16) Column 62, Claim 1, line 12, please delete "." after both "heteroary!":

Column 62, Claim 1, line 26, please delete "," after "arylcarbonyl";

18) Column 62, Claim 1, line 26, please delete the second "and" and insert therefor --or--:

19) Column 62, Claim 1, lines 36-37, please delete ", or a group of Formula I at position R1 thereof";

20) Column 62, Claim 1, line 39, please delete "group" and insert therefor -- radical of a compound--;

21) Column 62, Claim 1, line 40, please delete "nitrogen atom is Q4" and insert therefor -- radical is R1--

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Isis Pharmaceuticals, Inc. 1896 Rutherford Rd.

Carlsbad, CA 92008

This collection of information is required by 37 CFR 1.322, 1.233, and 1.324. The information is required to obtain or retain a benefit by the public which is to file und by the USFP (10 process) an application. Condinationally is governed by \$5 U.S. C.12 and \$7 CFR 1.14. This collection is estimated to 1 hour to complete, including gathering, preparing, and submitting the completed application form to the USFPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete is the man add or supplections for reducing the buildon, should be sent to the Child and call the completed application form to the USFPTO. The will vary depending upon the individual case. Any comments on the second of the comment of the complete or complete. Complete the buildon, should be sent to the Child a few to the Child and the Chil

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number:
(Also Form PT0-169)

### UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 3 of 11

PATENT NO. 7,244,847

APPLICATION NO.: 10/071,978 ISSUE DATE : 07/17/2007

INVENTOR(S) : Eric E. Swayze et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

22) Column 63, Claim 10, lines 39-43, please delete "

insert therefor --

23) Column 63, Claim 10, lines 58-66, please delete " "

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Isis Pharmaceuticals, Inc.

1896 Rutherford Rd.

Carlsbad, CA 92008

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is expaired to obtain or retain a benefit by the prable vehicle is to find only the ILSPOT to process) an application. Confidentially is governed by \$5 U.S. C. 122 and \$7 CFR 1.14. This collection is estimated that 0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time your require to complete in form analysis supplements for reducing this business, should be sent to the Chille State of the Complete of the Complet

### UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 4 of 11

PATENT NO. : 7.244.847

APPLICATION NO.: 10/071.978 ISSUE DATE : 07/17/2007

INVENTOR(S) : Eric E. Swayze et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- 25) Column 64. Claim 12. line 15. please delete ".":
- 26) Column 64, Claim 15, line 24, please delete ",";
- 27) Column 64, Claim 16, line 36, please delete "selected from" and insert therefor --substituted with--;

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Isis Pharmaceuticals, Inc.

1896 Butherford Bd

Carlsbad, CA 92008

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any

comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number (Also Form PTO-1050)

#### UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 5 of 11

PATENT NO. : 7.244.847

APPLICATION NO.: 10/071,978 ISSUE DATE : 07/17/2007

INVENTOR(S) : Eric E. Swayze et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

29) Column 65, Claim 17, lines 1-13, please delete "

" and insert therefor

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Isis Pharmaceuticals, Inc.

1896 Butherford Rd

Carlsbad, CA 92008

insert therefor -

This collection of information is required by 37 CFR 1,322, 1,323, and 1 324 The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(As Form PTO-1050)

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 6 of 11

PATENT NO. : 7,244,847

APPLICATION NO.: 10/071,978 ISSUE DATE : 07/17/2007

INVENTOR(S) : Eric E. Swavze et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

30) Column 65, Claim 17, lines 25-66, please delete "

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Isis Pharmaceuticals, Inc.

1896 Rutherford Rd.

Carlsbad, CA 92008

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to fire and by the USPTO to process an expedication. Confidentially is powered by \$3 U.S. C. 122 and 75 CFR 1.14. This collection is estimated to flow to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Arm comments on the seminant of time you require to complete in the man and suspections for reducing its builder, should be sent to the Critical collection. The comments of the service of the control of the comments of the service of the control of the comment of the service of the control of the comment of the control of the comment of the control of the control

U.S. Patent and Trademank office; U.S. Death of Chicago and Chicag

### UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page \_ 7\_ of \_ 11\_

PATENT NO. : 7,244,847 APPLICATION NO.: 10/071,978

ISSUE DATE : 07/17/2007

INVENTOR(S) : Eric E. Swavze et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Isis Pharmaceuticals, Inc.

1896 Rutherford Rd.

Carlsbad, CA 92008

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file and by the USFPTO to process an application. Confidentially is powered by \$5 U.S. C. 1.22 and \$7 CFR 1.1.4 This collection is estimated to 1 hour to complete, including gathering, preparing, and submitting the completed application form to the USFTO. Time will vary depending upon the individual case. Any comments on the mount of time you require to complete the form and/or supplections for reducing the building through the sent to the Collection of the control of t

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTC-1050)

# UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 8 of 11

APPLICATION NO.: 10/071,978

PATENT NO.

ISSUE DATE : 07/17/2007

INVENTOR(S) : Eric E. Swayze et al.

: 7,244,847

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Isis Pharmaceuticals, Inc.

1896 Rutherford Rd.

Carlsbad, CA 92008

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file under by the USFO to process) an application. Confidentially is govered by 35 U.S. C. 22 and 37 CFR 1.14. This collection is estimated to 1 hour to complete, including gathering, preparing, and submitting the completed application form to the USFTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete the form and/or suppensions for reducing this busterly, should be sent in the Chef India of Comments of the property of the completed application form to the USFTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suppensions for reducing this busterly, should be sent in the Chef India of Chef India or the USFTO. The Section of the Chef India of Chef India or The India of Chef India or The India of Chef India or The India of India or The India of India or India or

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTO-1050)

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 9 of 11

PATENT NO. : 7,244,847

APPLICATION NO.: 10/071,978 ISSUE DATE : 07/17/2007

INVENTOR(S) : Eric E. Swayze et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

and insert therefor ---

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Isis Pharmaceuticals, Inc.

1896 Rutherford Rd.

Carlsbad, CA 92008

This collection of information is required by 37 CFR 1322, 1323, and 1324. The information is required to obtain or retain a benefit by the public which is to find up the USPTO to process) an application. Confidentiality is governed by 35 U.S. C.12 and 37 CFR 1.14. This collection is estimated that 0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete is the time and/or supplections for reducing the burden, should be sent to the Chief and continued to Chief and the Chief an

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number (Also Form PTO-1050)

#### LINITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 10 of 11

PATENT NO. : 7,244,847 APPLICATION NO.: 10/071,978

ISSUE DATE : 07/17/2007

INVENTOR(S) : Eric E. Swavze et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

33) Column 66, Claim 18, lines 57-66, please delete

- 34) Column 67, Claim 20, line 17, please delete "Nsuccinimidyl" and insert therefor -- N-succinimidyl-;
- 35) Column 67, Claim 20, line 20, please delete ";" and insert therefor --,--;

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Isis Pharmaceuticals, Inc.

1896 Rutherford Rd. Carlsbad, CA 92008

This collection of information is required by 37 CFR 1 322, 1,323, and 1,324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

### UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 11 of 11

PATENT NO. : 7,244,847

APPLICATION NO.: 10/071 978 ISSUE DATE : 07/17/2007

INVENTOR(S) Eric E. Swayze et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

36) Column 67, Claim 21, lines 24-30, please delete and insert therefor

- 37) Column 68, Claim 21, lines 7-8, please delete "can form a succinimido or phthalimido" and insert therefor --form a N-succinimidyl, N-phthalimidyl, N-maleimidyl, N-napthalimidyl, N-pyromellitic diimidyl, Nbenzopyrrolidinyl or N-benzimidazol-l-yl-;
- 38) Column 68, claim 21, line 8, please delete "or a fused ring derivative thereof,";
- 39) Column 68, Claim 21, lines 9-10, please delete "succinimido or phthalimido" and "or fused ring derivative thereof"

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Isis Pharmaceuticals, Inc.

1896 Rutherford Rd. Carlshad, CA 92008

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file This collection of information is required by 37 CFR 1.3/2, 1.3/2, and 1.3/4. The information is required to obtain or retain a benefit by the public which is to fee day by the USFP to process) an application. Confidentially is powered by \$3 U.S. C. 12 and \$7 CFR 1.4. This collection is estimated to 1 beaut to commend to the process of the process o FORMS TO THIS ADDRESS, SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450